SCHEMBL797767

SCHEMBL797767

CCn1c2c(c3ccccc31)CCNC2=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.52
GSK3A P49840 2/20 0.49
GSK3B P49841 2/20 0.49
ALDH1A1 P00352 3/20 0.49
PTPN1 P18031 1/20 0.45
BRD4 O60885 4/20 0.44
KDM4E B2RXH2 5/20 0.43
HPGD P15428 4/20 0.43
HTT P42858 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.43
PARP1 P09874 1/20 0.42
BRD2 P25440 1/20 0.42
BRD3 Q15059 1/20 0.42
CREBBP Q92793 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391 0.78 BRD4 (0.64) BRD4BRD2BRD3CREBBPALB
SCHEMBL1392953 0.78 NPC1 (0.49) PDE5AGSK3AGSK3BPTPN1BRD4
SCHEMBL999391 0.76 LMNA (0.47) ALDH1A1KDM4EHPGDHTTMEN1
SCHEMBL11632708 0.76 HTR6 (0.49) PARP1ALBBCHEACHE
SCHEMBL797994 0.75 MEN1 (0.48) PDE5AGSK3AGSK3BALDH1A1BRD4
SCHEMBL275697 0.74 KDM4E (0.49) PDE5AGSK3AGSK3BALDH1A1KDM4E
SCHEMBL9615137 0.71 HTR2A (0.55) ALDH1A1KDM4EMAPK1HSD17B10
SCHEMBL16102588 0.70 KDR (0.45) PDE5AALDH1A1BRD4HPGDPARP1
Hydrochloric Acid SCHEMBL9696491 0.70 KDM4E (0.56) ALDH1A1KDM4EMAPK1HSD17B10
SCHEMBL4298468 0.68 AKR1B10 (0.54) ALDH1A1PTPN1KDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 PDE5A 716/4885GSK3A 267/4885GSK3B 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.